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The ULICE project started in 2009 to address two different 
complementary issues: the development of the appropriate 
instruments for hadrontherapy, with emphasis on carbon ion 
therapy, and the need for intensive collaboration among the 
existing and planned centres, as well as with the European 
hadrontherapy community at large. ULICE was funded by the 
European Commission and involved 20 European institutions 
coordinated by CNAO in Pavia. All the existing and planned 
European ion therapy facilities were involved in the project, 
together with two research centres (CERN and GSI) and 
industrial companies. The approach of ULICE to 
hadrontherapy dealed with all its aspects from medical 
physics to radiobiology, from accelerators to particle beams 
in clinics. The experience being built up in Heidelberg (HIT), 
with more than 2000 patients treated, and Pavia with more 
than 500 patients treated, helped the development of 
hadrontherapy in Europe and provided patients throughout 
Europe access to these centres with treatment according to 
standardized protocols. In addition, other centres planned in 
Europe (MedAustron) which are due to start, ware benefit 
from this experience. One of the most relevant results of the 
ULICE project was the establishment of an international 
board – IONTREB International Ion Beam Therapy Research 
Board - focusing on clinical aspects of the hadrontherapy. 
The project consisted of 3 pillars, Joint Research Activities – 
focused on the development of instruments and protocols, 
Networking – to increase cooperation between facilities and 
research communities, and Transnational access – to allow 
access to hadrontherapy facilities to researchers wanting to 
perform radiobiological and physics experiments as well as 
clinical studies. The Joint Research Activities was 
coordinated by the Medical University of Vienna and focused 
on improving the performance of hadrontherapy facilities 
through the development of various instruments. The JRA 
pillar dealed with clinical issues such as developing novel 
adaptive treatment planning, including clinical protocols that 
combine different types of irradiations, and developing a 
computer assisted patient selection program accessible to 
the whole European community; this was not only enable an 
efficient patient referral to the existing facilities, but also 
allow to pursue the clinical research focused on tumours with 
specific biological characteristics and/or critical location. 
These tools provided a research infrastructure producing 
scientifically sound evidence on the efficacy of 
hadrontherapy. Among the technical issues that ULICE will 
address through JRA is the challenge of reducing the 
dimensions and cost of the gantries. The Networking 
Activities pillar was coordinated by CERN and focuses on 
communication, interaction and interdisciplinary discussion 
among the 20 partners and with the external world, and 
dissemination of the project results to the wider community 
involved in cancer care. Networking activities provided the 
external research community with a clear knowledge of what 
is possible and what is needed in terms of research to be 
carried out at the facilities (both through dissemination 
activities, residential training for researchers and through 
scientific events and publications). The Transnational Access 
was coordinated by the University Hospital of Heidelberg, 
and aims at providing access, at HIT and CNAO, for external 
researchers to the ion therapy facilities for preclinical 
research with the available beams of particles. Beam time 
was allocated to the external researchers through a review 
committee, that assessed the scientific impact of the 
proposed research project. The Transnational Access pillar 
also produced agreed protocols for multi centric clinical 
trials, and allowed external researchers to participate in 
these trials. These goals were facilitated making an extensive 
use of advanced e-science grid technology. 
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Radiation therapy represents an important part of 
multimodal cancer therapy in children. Due to increasing 
efficacy of cancer therapy overall treatment outcomes 
considerably improved. Over the last about 50 years the 
situation in childhood malignancies has changed from an 
inevitably fatal condition to one that is potentially curable, 
with overall 5-year survival rates approaching 80%. However, 
it is well understood that growing tissues are particularly 
sensitive to radiation injury. The burden of multimodal 
treatment consisting often of surgery, cytotoxic and radiation 
therapy jeopardizes the future life of the patients. 
Therefore, reduction of late sequelae and improvement of 
quality of life have become a major concern in paediatric 
cancer survivors.  
Proton beam therapy (PT) has become of increasing interest 
in paediatric oncology. Several dosimetric studies clearly 
demonstrated that PT can better limit the irradiated volume 
as compared to photon technique. Therefore, PT is a 
promising method to reduce the risk for acute and late 
effects, especially with regard to paediatric tumors. Over the 
last decades clinical experience in PT in childhood cancer 
was restricted due to limited availability and very few 
facilities being hospital based. So far, prospective approaches 
were missing, cohorts were small and observation times 
short,  especially  with  regard  to  very  young  children  being  
treated with PT. However, the number of children being 
treated with protons for solid tumors is currently increasing 
due to a growing number of proton facilities being in 
operation worldwide. In Europe and US common indications 
for treatment with PT in the paediatric cohort are as well 
local tumors of central nervous system (CNS) (i.e. glioma, 
medulloblastoma, ependymoma, craniopharyngeoma, and 
intracranial germ cell tumors) as non-CNS tumors (i.e. 
chordoma/chondrosarcoma, and rhabdomyosarcoma). 
Treatment results are promising with regard to local control 
rates. Recent data on neurocognitive functioning and quality 
of life seem to confirm favourable outcome after PT. 
Additional, first experiences suggest that secondary cancer 
induction can be reduced when using PT. Still, more clinical 
data will need to emerge and to quantify the clinical benefit 
of PT. Therefore, PT should be established in a prospective 
approach within multimodality cancer concepts to 
ensure optimal treatment and careful future evaluation. 
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